Abstract | TOPIC: CLINICAL RELEVANCE: Ocular inflammatory diseases remain a leading cause of vision loss worldwide. Anti-TNF-α agents are used widely in treatment of rheumatologic diseases. A committee of the American Uveitis Society performed a systematic review of literature to generate guidelines for use of these agents in ocular inflammatory conditions. METHODS: A systematic review of published studies was performed. Recommendations were generated using the Grading of Recommendations Assessment, Development, and Evaluation group criteria. RESULTS: Numerous studies including controlled clinical trials have demonstrated that anti-TNF-α biologic agents (in particular infliximab and adalimumab) are effective in the treatment of severe ocular inflammatory disease. Based on these studies, the expert panel makes the following recommendations. CONCLUSIONS:
|
Authors | Grace Levy-Clarke, Douglas A Jabs, Russell W Read, James T Rosenbaum, Albert Vitale, Russell N Van Gelder |
Journal | Ophthalmology
(Ophthalmology)
Vol. 121
Issue 3
Pg. 785-96.e3
(Mar 2014)
ISSN: 1549-4713 [Electronic] United States |
PMID | 24359625
(Publication Type: Consensus Development Conference, Journal Article, Practice Guideline, Research Support, Non-U.S. Gov't, Systematic Review)
|
Copyright | Copyright © 2014 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Anti-Inflammatory Agents
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Immunoglobulin Fab Fragments
- Immunoglobulin G
- Immunosuppressive Agents
- Receptors, Tumor Necrosis Factor
- Tumor Necrosis Factor-alpha
- Polyethylene Glycols
- golimumab
- Infliximab
- Adalimumab
- Etanercept
- Certolizumab Pegol
|
Topics |
- Adalimumab
- Anti-Inflammatory Agents
(therapeutic use)
- Antibodies, Monoclonal
(therapeutic use)
- Antibodies, Monoclonal, Humanized
(therapeutic use)
- Arthritis, Juvenile
(drug therapy)
- Behcet Syndrome
(diagnosis, drug therapy)
- Certolizumab Pegol
- Etanercept
- Humans
- Immunoglobulin Fab Fragments
(therapeutic use)
- Immunoglobulin G
(therapeutic use)
- Immunosuppressive Agents
(therapeutic use)
- Infliximab
- Ophthalmology
(organization & administration)
- Polyethylene Glycols
(therapeutic use)
- Receptors, Tumor Necrosis Factor
(therapeutic use)
- Scleritis
(diagnosis, drug therapy)
- Societies, Medical
(organization & administration)
- Spondylarthropathies
(drug therapy)
- Tumor Necrosis Factor-alpha
(antagonists & inhibitors)
- United States
- Uveitis
(diagnosis, drug therapy, etiology)
|